31-40 of 83 results
Linklaters Insights: Novel Coronavirus - practice guide of significant commercial and legal issues
The recent outbreak of the novel coronavirus is causing disruption across greater China and the region. This cross-practice guide from our colleagues at Linklaters highlights key issues that may affect business operations in the current environment. ...
TGA guidance on the promotion of medicinal cannabis
The Therapeutic Goods Administration (TGA) has issued guidance on advertising to the public for businesses involved with medicinal cannabis products and therapies. Along with advertising restrictions, ...
TGA guidance on the promotion of stem cells and HCT products
The Therapeutic Goods Administration has issued advertising guidance for businesses involved with stems cells and other human cell or tissue products. ...
Healthcare trend watch 2019
The healthcare team at Allens reports on some key trends and sectors to look out for in 2020. ...
Allens advises Cigna on new health venture
The joint venture will aim to offer a range of services for the benefit of health fund members in Australia, to deliver better health outcomes and risk management. Each company will contribute $10 ...
Dixon Hospitality says cheers to Beer DeLuxe
Allens has advised Dixon Hospitality on its acquisition of the Beer DeLuxe venues in NSW and Victoria. Dixon has acquired six venues including those in the entertainment precincts of King Street ...
Allens helps deliver a healthy hospital outcome
Allens has advised the Plenary Health consortium on the expansion of the existing Casey Hospital through a series of transactions that closed late last week. The expansion will significantly increa ...
High Court unanimously finds isolated genetic material not patentable
In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...
Unexpected risks of the IoT revolution: Cyber security in medical devices
In late August 2017 the US Food and Drug Administration recalled 465000 Abbott Laboratories pacemakers due to cyber security vulnerabilities Although this was the first time that the FDA had recalled a medical device because of cyber concerns they have been alive to the significant risk that a cyber ...
OAIC concludes investigation of Australian Red Cross data breach
OAIC concludes investigation of Australian Red Cross data breach where a one-off human error by a third party provider's employee led to a massive data breach that hit the Australian Red Cross Blood Service ...